The Role of Different Monocyte Subsets in the Pathogenesis of Atherosclerosis and Acute Coronary Syndromes

Scandinavian Journal of Immunology

Volumn 82, Issue 3, 2015, Pages 163-173

  Idzkowska, E ^a   Eljaszewicz, A ^a   Miklasz, P ^a   Musial, W J ^a   Tycinska, A M ^a   Moniuszko, Marcin ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD14 ANTIGEN; CD16 ANTIGEN; COMPLEMENT; OPSONIN; SCAVENGER RECEPTOR; FC RECEPTOR; FCGR3B PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN;

ACUTE CORONARY SYNDROME; ANTIGEN EXPRESSION; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL FUNCTION; CELL SUBPOPULATION; HUMAN; MACROPHAGE ACTIVATION; MONOCYTE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; ATHEROSCLEROTIC PLAQUE; CELL ADHESION; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY; RISK FACTOR;

ACUTE CORONARY SYNDROME; ANTIGENS, CD14; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CELL ADHESION; GPI-LINKED PROTEINS; HUMANS; INFLAMMATION; MONOCYTES; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, IGG; RISK FACTORS;

EID: 84939241095     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12314     Document Type: Review

References (128)

1. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011;12:204-12.
2. Alamanda V, Singh S, Lawrence NJ, Chellappan SP. Nicotine-mediated induction of E-selectin in aortic endothelial cells requires Src kinase and E2F1 transcriptional activity. Biochem Biophys Res Commun 2012;418 :56-61.
3. Alvarez A, Cerda-Nicolas M, Naim Abu Nabah Y et al. Direct evidence of leukocyte adhesion in arterioles by angiotensin II. Blood 2004;104:402-8.
4. Eriksson EE, Werr J, Guo Y, Thoren P, Lindbom L. Direct observations in vivo on the role of endothelial selectins and alpha(4) integrin in cytokine-induced leukocyte-endothelium interactions in the mouse aorta. Circ Res 2000;86 :526-33.
5. Riou S, Mees B, Esposito B et al. High pressure promotes monocyte adhesion to the vascular wall. Circ Res 2007;100 :1226-33.
6. Wang S, Peng Q, Zhang J, Liu L. Na+/H+ exchanger is required for hyperglycaemia-induced endothelial dysfunction via calcium-dependent calpain. Cardiovasc Res 2008;80 :255-62.
7. Collins RG, Velji R, Guevara NV, Hicks MJ, Chan L, Beaudet AL. P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. J Exp Med 2000;191 :189-94.
8. Luscinskas FW, Kansas GS, Ding H et al. Monocyte rolling, arrest and spreading on IL-4-activated vascular endothelium under flow is mediated via sequential action of L-selectin, beta 1-integrins, and beta 2-integrins. J Cell Biol 1994;125 :1417-27.
9. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007;7 :678-89.
10. Koenen RR, von Hundelshausen P, Nesmelova IV et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med 2009;15:97-103.
11. Gleissner CA, Shaked I, Little KM, Ley K. CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages. J Immunol 2010;184:4810-8.
12. Tacke F, Alvarez D, Kaplan TJ et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 2007;117 :185-94.
13. Combadiere C, Potteaux S, Rodero M et al. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 2008;117:1649-57.
14. van der Wal AC, Das PK, Tigges AJ, Becker AE. Adhesion molecules on the endothelium and mononuclear cells in human atherosclerotic lesions. Am J Pathol 1992;141 :1427-33.
15. Gui T, Shimokado A, Sun Y, Akasaka T, Muragaki Y. Diverse roles of macrophages in atherosclerosis: from inflammatory biology to biomarker discovery. Mediators Inflamm 2012;2012:693083.
16. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987;84:2995-8.
17. Kuchibhotla S, Vanegas D, Kennedy DJ et al. Absence of CD36 protects against atherosclerosis in ApoE knock-out mice with no additional protection provided by absence of scavenger receptor A I/II. Cardiovasc Res 2008;78:185-96.
18. Kunjathoor VV, Febbraio M, Podrez EA et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 2002;277 :49982-8.
19. Sakaguchi H, Takeya M, Suzuki H et al. Role of macrophage scavenger receptors in diet-induced atherosclerosis in mice. Lab Invest 1998;78:423-34.
20. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993;69 :377-81.
21. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol 2005;46:937-54.
22. Gough PJ, Gomez IG, Wille PT, Raines EW. Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J Clin Invest 2006;116 :59-69.
23. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94 :2493-503.
24. Newby AC. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol 2008;28 :2108-14.
25. Passlick B, Flieger D, Ziegler-Heitbrock HW. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood 1989;74:2527-34.
26. Ziegler-Heitbrock HW, Ströbel M, Fingerle G et al. Small (CD14+/CD16+) monocytes and regular monocytes in human blood. Pathobiology 1991;59 :127-30.
27. Ziegler-Heitbrock HW, Fingerle G, Ströbel M et al. The novel subset of CD14+/CD16+ blood monocytes exhibits features of tissue macrophages. Eur J Immunol 1993;23 :2053-8.
28. Fingerle G, Pforte A, Passlick B, Blumenstein M, Ströbel M, Ziegler-Heitbrock HW. The novel subset of CD14+/CD16+ blood monocytes is expanded in sepsis patients. Blood 1993;82 :3170-6.
29. Ancuta P, Rao R, Moses A et al. Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med 2003;197:1701-7.
30. Ziegler-Heitbrock L, Ancuta P, Crowe S et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010;116:e74-80.
31. Hristov M, Schmitz S, Schuhmann C et al. An optimized flow cytometry protocol for analysis of angiogenic monocytes and endothelial progenitor cells in peripheral blood. Cytometry A 2009;75 :848-53.
32. Zawada AM, Rogacev KS, Schirmer SH et al. Monocyte heterogeneity in human cardiovascular disease. Immunobiology 2012;217:1273-84.
33. Heimbeck I, Hofer TP, Eder C et al. Standardized single-platform assay for human monocyte subpopulations: Lower CD14+CD16++ monocytes in females. Cytometry A 2010;77 :823-30.
34. Wong KL, Tai JJ, Wong WC et al. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood 2011;118:e16-31.
35. Stec M, Baran J, Baj-Krzyworzeka M et al. Chemokine receptors and chemokine production by CD34+ stem cell-derived monocytes in response to cancer cells. Anticancer Res 2012;32 :4749-53.
36. Cros J, Cagnard N, Woollard K et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 2010;33:375-86.
37. Zawada AM, Rogacev KS, Rotter B et al. SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood 2011;118:50-61.
38. Smedman C, Ernemar T, Gudmundsdotter L et al. FluoroSpot analysis of TLR-activated monocytes reveals several distinct cytokine secreting subpopulations. Scand J Immunol 2012;75 :249-58.
39. Tallone T, Turconi G, Soldati G, Pedrazzini G, Moccetti T, Vassalli G. Heterogeneity of human monocytes: an optimized four-color flow cytometry protocol for analysis of monocyte subsets. J Cardiovasc Transl Res 2011;4 :211-9.
40. Auffray C, Fogg D, Garfa M et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 2007;317:666-70.
41. Randolph GJ, Sanchez-Schmitz G, Liebman RM, Schäkel K. The CD16(+) (FcgammaRIII(+)) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting. J Exp Med 2002;196 :517-27.
42. Belge KU, Dayyani F, Horelt A et al. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol 2002;168 :3536-42.
43. Frankenberger M, Sternsdorf T, Pechumer H, Pforte A, Ziegler-Heitbrock HWL. Differential cytokine expression in human blood monocyte subpopulations: a polymerase chain reaction analysis. Blood 1996;87:373.
44. Moniuszko M, Liyanage NP, Doster MN et al. Glucocorticoid treatment at moderate doses of SIVmac251-infected rhesus macaques decreases the frequency of circulating CD14+CD16++ monocytes but does not alter the tissue virus reservoir. AIDS Res Hum Retroviruses 2015;31:115-26.
45. Dutertre CA, Amraoui S, DeRosa A et al. Pivotal role of M-DC8(+) monocytes from viremic HIV-infected patients in TNFalpha overproduction in response to microbial products. Blood 2012;120:2259-68.
46. Power CP, Wang JH, Manning B et al. Bacterial lipoprotein delays apoptosis in human neutrophils through inhibition of caspase-3 activity: regulatory roles for CD14 and TLR-2. J Immunol 2004;173 :5229-37.
47. Merino A, Buendia P, Martin-Malo A, Aljama P, Ramirez R, Carracedo J. Senescent CD14 + CD16 + monocytes exhibit proinflammatory and proatherosclerotic activity. J Immunol 2011;186:1809-15.
48. Sunderkötter C, Nikolic T, Dillon MJ et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol 2004;172:4410-7.
49. Rogacev KS, Zawada AM, Hundsdorfer J et al. Immunosuppression and monocyte subsets. Nephrol Dial Transplant 2015;30 :143-53.
50. Stec M, Weglarczyk K, Baran J et al. Expansion and differentiation of CD14 + CD16(-) and CD14 + +CD16 + human monocyte subsets from cord blood CD34 + hematopoietic progenitors. J Leukoc Biol 2007;82 :594-602.
51. Tacke F, Randolph GJ. Migratory fate and differentiation of blood monocyte subsets. Immunobiology 2006;211 :609-18.
52. Rogacev KS, Seiler S, Zawada AM et al. CD14 + +CD16 + monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur Heart J 2011;32:84-92.
53. Gonzalez P, Alvarez R, Batalla A et al. Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immun 2001;2:191-5.
54. Muntinghe FL, Verduijn M, Zuurman MW et al. CCR5 deletion protects against inflammation-associated mortality in dialysis patients. J Am Soc Nephrol 2009;20:1641-9.
55. Pai JK, Kraft P, Cannuscio CC et al. Polymorphisms in the CC-chemokine receptor-2 (CCR2) and -5 (CCR5) genes and risk of coronary heart disease among US women. Atherosclerosis 2006;186:132-9.
56. Rossol M, Kraus S, Pierer M, Baerwald C, Wagner U. The CD14(bright) CD16? monocyte subset is expanded in rheumatoid arthritis and promotes Th17 expansion. Arthritis Rheum 2012;64:671-7.
57. Skrzeczyńska-Moncznik J, Bzowska M, Loseke S, Grage-Griebenow E, Zembala M, Pryjma J. Peripheral blood CD14high CD16 + monocytes are main producers of IL-10. Scand J Immunol 2008;67:152-9.
58. Shantsila E, Wrigley B, Tapp L et al. Immunophenotypic characterization of human monocyte subsets: possible implications for cardiovascular disease pathophysiology. J Thromb Haemost 2011;9 :1056-66.
59. Ulrich C, Heine GH, Garcia P et al. Increased expression of monocytic angiotensin-converting enzyme in dialysis patients with cardiovascular disease. Nephrol Dial Transplant 2006;21:1596-602.
60. Venneri MA, De Palma M, Ponzoni M et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 2007;109:5276-85.
61. Gamberg CG, Valmu L, Fagerholm S et al. Leukocyte integrins and inflammation. Cell Mol Life Sci 1998;54:549-55.
62. Gray JL, Shankar R. Down regulation of CD11b and CD18 expression in atherosclerotic lesion-derived macrophages. Am Surg 1995;61 :674-9.
63. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A 1979;76 :333-7.
64. Moore KJ, Freeman MW. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol 2006;26 :1702-11.
65. Plüddemann A, Neyen C, Gordon S. Macrophage scavenger receptors and host-derived ligands. Methods 2007;43 :207-17.
66. Li L, Sawamura T, Renier G. Glucose enhances human macrophage LOX-1 expression: role for LOX-1 in glucose-induced macrophage foam cell formation. Circ Res 2004;94 :892-901.
67. Fukuhara-Takaki K, Sakai M, Sakamoto Y, Takeya M, Horiuchi S. Expression of class A scavenger receptor is enhanced by high glucose in vitro and under diabetic conditions in vivo: one mechanism for an increased rate of atherosclerosis in diabetes. J Biol Chem 2005;280 :3355-64.
68. Griffin E, Re A, Hamel N et al. A link between diabetes and atherosclerosis: glucose regulates expression of CD36 at the level of translation. Nat Med 2001;7 :840-6.
69. Lang KS, Lang PA, Meryk A et al. Involvement of Toso in activation of monocytes, macrophages, and granulocytes. Proc Natl Acad Sci U S A 2013;110 :2593-8.
70. Honjo K, Kubagawa Y, Kubagawa H. Is Toso/IgM Fc receptor (FcμR) expressed by innate immune cells? Proc Natl Acad Sci U S A 2013;110 :E2540-1.
71. Sigruener A, Buechler C, Bared SM et al. E-LDL upregulates TOSO expression and enhances the survival of human macrophages. Biochem Biophys Res Commun 2007;359 :723-8.
72. Foster GA, Gower RM, Stanhope KL, Havel PJ, Simon SI, Armstrong EJ. On-chip phenotypic analysis of inflammatory monocytes in atherogenesis and myocardial infarction. Proc Natl Acad Sci U S A 2013;110 :13944-9.
73. Rothe G, Gabriel H, Kovacs E et al. Peripheral blood mononuclear phagocyte subpopulations as cellular markers in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1996;16 :1437-47.
74. Sulicka J, Surdacki A, Mikołajczyk T et al. Elevated markers of inflammation and endothelial activation and increased counts of intermediate monocytes in adult survivors of childhood acute lymphoblastic leukemia. Immunobiology 2013;218 :810-6.
75. Allavena P, Piemonti L, Longoni D et al. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 1998;28 :359-69.
76. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3 :23-35.
77. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23 :549-55.
78. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004;25 :677-86.
79. Mantovani A, Garlanda C, Locati M. Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler Thromb Vasc Biol 2009;29:1419-23.
80. Hamilton TA. Molecular basis of macrophage activation: from gene expression to phenotypic diversity. In: Burke B, Lewis CE, eds. The Macrophage. 2nd edn. New York: Oxford University Press, 2002: pp. 73-102.
81. Verreck FA, de Boer T, Langenberg DM et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci U S A 2004;101 :4560-5.
82. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 1992;176:287-92.
83. Mosser DM. The many faces of macrophage activation. J Leukoc Biol 2003;73:209-12.
84. Eljaszewicz A, Wiese M, Helmin-Basa A et al. Collaborating with the enemy: function of macrophages in the development of neoplastic disease. Mediators Inflamm 2013;2013:831387.
85. Angiolillo AL, Sgadari C, Taub DD et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995;182 :155-62.
86. Goerdt S, Orfanos CE. Other functions, other genes: alternative activation of antigen-presenting cells. Immunity 1999;10 :137-42.
87. Noel W, Raes G, Hassanzadeh GH, De Baetselier P, Beschin A. Alternatively activated macrophages during parasite infections. Trends Parasitol 2004;20:126-33.
88. Jetten N, Verbruggen S, Gijbels MJ, Post MJ, De Winther MP, Donners MM. Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo. Angiogenesis 2014;17:109-18.
89. Lee CG et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 2001;194:809-21.
90. Sierra-Filardi E, Vega MA, Sanchez-Mateos P, Corbi AL, Puig-Kroger A. Heme oxygenase-1 expression in M-CSF-polarized M2 macrophages contributes to LPS-induced IL-10 release. Immunobiology 2010;215:788-95.
91. Spencer M et al. Adipose tissue macrophages in insulin-resistant subjects are associated with collagen VI and fibrosis and demonstrate alternative activation. Am J Physiol Endocrinol Metab 2010;299:E1016-27.
92. Stöger JL, Gijbels MJ, van der Velden S et al. Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis 2012;225 :461-8.
93. Rothe G, Herr AS, Stöhr J, Abletshauser C, Weidinger G, Schmitz G. A more mature phenotype of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart disease. Atherosclerosis 1999;144 :251-61.
94. Kontush A, Chapman MJ. Antiatherogenic small, dense HDL guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006;3:144-53.
95. Krychtiuk KA, Kastl SP, Pfaffenberger S et al. Small high-density lipoprotein is associated with monocyte subsets in stable coronary artery disease. Atherosclerosis 2014;237 :589-96.
96. Rogacev KS, Zawada AM, Emrich I et al. Lower Apo A-I and lower HDL-C levels are associated with higher intermediate CD14 + +CD16 + monocyte counts that predict cardiovascular events in chronic kidney disease. Arterioscler Thromb Vasc Biol 2014;34 :2120-7.
97. Kapinsky M, Torzewski M, Büchler C, Duong CQ, Rothe G, Schmitz G. Enzymatically degraded LDL preferentially binds to CD14(high) CD16(+) monocytes and induces foam cell formation mediated only in part by the class B scavenger-receptor CD36. Arterioscler Thromb Vasc Biol 2001;21 :1004-10.
98. Czepluch FS, Bergler A, Waltenberger J. Hypercholesterolaemia impairs monocyte function in CAD patients. J Intern Med 2007;261 :201-4.
99. Serrano CV Jr, Yoshida VM, Venturinelli ML et al. Effect of simvastatin on monocyte adhesion molecule expression in patients with hypercholesterolemia. Atherosclerosis 2001;157 :505-12.
100. Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997;30 :1212-7.
101. Ferro D, Parrotto S, Basili S, Alessandri C, Violi F. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 2000;36 :427-31.
102. Ganné F, Vasse M, Beaudeux JL et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes-a possible protective mechanism against atherothrombosis. Thromb Haemost 2000;84 :680-8.
103. Poitou C, Dalmas E, Renovato M et al. CD14dimCD16 + and CD14 + CD16 + monocytes in obesity and during weight loss: relationships with fat mass and subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 2011;31:2322-30.
104. Timmerman KL, Flynn MG, Coen PM, Markofski MM, Pence BD. Exercise training-induced lowering of inflammatory (CD14 + CD16 + ) monocytes: a role in the anti-inflammatory influence of exercise? J Leukoc Biol 2008;84:1271-8.
105. Rogacev KS, Ulrich C, Blömer L et al. Monocyte heterogeneity in obesity and subclinical atherosclerosis. Eur Heart J 2010;31:369-76.
106. Schlitt A, Heine GH, Blankenberg S et al. CD14 + CD16 + monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. Thromb Haemost 2004;92:419-24.
107. Kashiwagi M, Imanishi T, Tsujioka H et al. Association of monocyte subsets with vulnerability characteristics of coronary plaques as assessed by 64-slice multidetector computed tomography in patients with stable angina pectoris. Atherosclerosis 2010;212:171-6.
108. Imanishi T, Ikejima H, Tsujioka H et al. Association of monocyte subset counts with coronary fibrous cap thickness in patients with unstable angina pectoris. Atherosclerosis 2010;212:628-35.
109. Heine GH, Ortiz A, Massy ZA et al. Monocyte subpopulations and cardiovascular risk in chronic kidney disease. Nat Rev Nephrol 2012;8:362-9.
110. Rogacev KS, Cremers B, Zawada AM et al. CD14 + +CD16 + monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol 2012;60:1512-20.
111. Berg KE, Ljungcrantz I, Andersson L et al. Elevated CD14 + +CD16- monocytes predict cardiovascular events. Circ Cardiovasc Genet 2012;5:122-31.
112. Mehta NN, Reilly MP. Monocyte mayhem: do subtypes modulate distinct atherosclerosis phenotypes? Circ Cardiovasc Genet 2012;5 :7-9.
113. Cardilo-Reis L, Witztum JL, Binder CJ. When monocytes come (Too) close to our hearts. J Am Coll Cardiol 2010;55:1639-41.
114. Gullestad L, Ueland T, Vinge LE, Finsen A, Yndestad A, Aukrust P. Inflammatory cytokines in heart failure: mediators and markers. Cardiology 2012;122:23-35.
115. Nozawa N, Hibi K, Endo M et al. Association between circulating monocytes and coronary plaque progression in patients with acute myocardial infarction. Circ J 2010;74:1384-91.
116. Tsujioka H, Imanishi T, Ikejima H et al. Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction. J Am Coll Cardiol 2009;54:130-8.
117. van der Laan AM, Hirsch A, Robbers LF et al. A proinflammatory monocyte response is associated with myocardial injury and impaired functional outcome in patients with ST-segment elevation myocardial infarction: monocytes and myocardial infarction. Am Heart J 2012;163:57-65.
118. Ozaki Y, Imanishi T, Tanimoto T et al. Effect of direct renin inhibitor, aliskiren, on peripheral blood monocyte subsets and myocardial salvage in patients with primary acute myocardial infarction. Circ J 2012;76:1461-8.
119. van der Laan AM, Ter Horst EN, Delewi R et al. Monocyte subset accumulation in the human heart following acute myocardial infarction and the role of the spleen as monocyte reservoir. Eur Heart J 2014;35:376-85.
120. Tapp LD, Shantsila E, Wrigley BJ, Pamukcu B, Lip GY. The CD14++CD16+ monocyte subset and monocyte-platelet interactions in patients with ST-elevation myocardial infarction. J Thromb Haemost 2012;10:1231-41.
121. Tapp LD, Shantsila E, Wrigley BJ, Montoro-Garcia S, Lip GY. TLR4 expression on monocyte subsets in myocardial infarction. J Intern Med 2013;273:294-305.
122. Shantsila E, Tapp LD, Wrigley BJ, Montoro-García S, Lip GY. CXCR4 positive and angiogenic monocytes in myocardial infarction. Thromb Haemost 2013;109:255-62.
123. Czepluch FS, Schlegel M, Bremmer F, Behnes CL, Hasenfuss G, Schäfer K. Stage-dependent detection of CD14+ and CD16+ cells in the human heart after myocardial infarction. Virchows Arch 2013;463:459-69.
124. Leers MP, Keuren JF, Frissen ME, Huts M, Kragten JA, Jie KS. The pro- and anticoagulant role of blood-borne phagocytes in patients with acute coronary syndrome. Thromb Haemost 2013;110:101-9.
125. Fukuda D, Shimada K, Tanaka A, Kawarabayashi T, Yoshiyama M, Yoshikawa J. Circulating monocytes and in-stent neointima after coronary stent implantation. J Am Coll Cardiol 2004;43:18-23.
126. Liu Y, Imanishi T, Ikejima H et al. Association between circulating monocyte subsets and in-stent restenosis after coronary stent implantation in patients with ST-elevation myocardial infarction. Circ J 2010;74:2585-91.
127. Montange D, Davani S, Deschaseaux F et al. The number of circulating CD14(+) cells is related to infarct size and postinfarct volumes in ST segment elevation myocardial infarction but not non-ST segment elevation myocardial infarction. Exp Clin Cardiol 2012;17:131-5.
128. Arslan U, Kocaoğlu I, Balci MM, Gülkan B, Falay MY, Temizhan A. Monocyte heterogeneity in myocardial infarction with and without ST elevation and its association with angiographic findings. Coron Artery Dis 2013;24:404-11.